<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927988</url>
  </required_header>
  <id_info>
    <org_study_id>MCHHFoshan-2101</org_study_id>
    <nct_id>NCT04927988</nct_id>
  </id_info>
  <brief_title>Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion</brief_title>
  <official_title>Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion: A Prospective, Single-center, Open, and Single-arm Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maternal and Child Health Hospital of Foshan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maternal and Child Health Hospital of Foshan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placenta accreta spectrum (PAS) disorders are associated with increased maternal morbidity&#xD;
      and mortality related to life-threatening hemorrhage, and greater potential need for blood&#xD;
      transfusion. Clinical evidences have confirmed that the use of autologous blood cell&#xD;
      transfusion is safe and effective for patients with obstetric haemorrhage. Normal saline is&#xD;
      the solution recommended for red cell washing, administration and salvage. However, there is&#xD;
      growing concern that normal saline is more toxic than balanced, buffered crystalloids such as&#xD;
      Lactated Ringer's and Plasma-Lyte. The purpose of this study is to evaluate the blood&#xD;
      components using of Ringer's Lactated by a prospective, single-center, open, and single-arm&#xD;
      clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>erythrocytes (/ÂµL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>hemoglobin (g/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematological parameters</measure>
    <time_frame>Baseline (Day 1), until 2 days after autotransfusion</time_frame>
    <description>Mean corpuscular volume (fL)</description>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Placenta Accreta Spectrum</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ringer's Lactated</intervention_name>
    <description>Using of Ringer's Lactated In Autologous Blood Cell Transfusion</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18 and 45 years old&#xD;
&#xD;
          -  Without health problem nor disease requiring regular medical treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subject with contraindication for drawing blood&#xD;
&#xD;
          -  Subject with physical or mental disability or restriction of liberty that would&#xD;
             prevent autotransfusion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhengping Liu, MD</last_name>
    <phone>86 757 82969772</phone>
    <email>liuzphlk81@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dazhi Fan, MD</last_name>
    <phone>86 757 82969772</phone>
    <email>fandazhigw@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maternal and Child Health Hospital of Foshan</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <zip>528000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhengping Liu, MD</last_name>
      <phone>86 757 82969772</phone>
      <email>liuzphlk81@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>Dazhi Fan, MD</last_name>
      <phone>86 757 82969772</phone>
      <email>fandazhigw@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Placenta Accreta Spectrum</keyword>
  <keyword>Autologous Blood Cell Transfusion</keyword>
  <keyword>Blood Components</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placenta Accreta</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

